Introduction
============

Epithelial ovarian cancer (EOC) is the leading cause of cancer-related deaths in women worldwide and remains the most lethal gynecological cancer \[[@b1-crt-2018-312]\]. Although the incidence of EOC has traditionally been lower in Korea than in western countries, including the United States and United Kingdom, it has steadily increased over the last few decades because of lifestyle and environmental changes \[[@b2-crt-2018-312]\]. In 1999, the age-standardized rates for annual EOC incidence and mortality in Korea were 5.0 and 1.7 per 100,000 women-years, respectively, which significantly increased to 6.4 and 2.3 per 100,000 women-years, respectively, by 2014 (both, p \< 0.05) \[[@b3-crt-2018-312]\]. Such increases represent a significant challenge to overcome, and methods for controlling the increasing rates of this cancer are urgently needed.

Defects in *BRCA1/2* tumor suppressor genes are the most frequently identified genetic changes associated with ovarian cancer. A *BRCA1/2* germline mutation is associated with poor prognostic factors, including early-onset cancer, serous histology, and advanced cancer stages \[[@b4-crt-2018-312]\]. However, in recent years, accumulating evidence has shown that *BRCA1/2* mutations are associated with improved survival and improved response to not only platinum-based chemotherapy \[[@b5-crt-2018-312],[@b6-crt-2018-312]\] but also targeted therapy using poly(ADP-ribose) polymerase inhibitors \[[@b7-crt-2018-312],[@b8-crt-2018-312]\].

Although there have been several reports of *BRCA1/2* mutation analyses in ovarian and breast cancer cases from Asian populations, there is relatively limited data for the Korean ovarian cancer (KoOC) population. Until now, there have been four independent studies on *BRCA1/2* mutations in KoOC patients; however, all of these were relatively small-scale, single-center studies with marked inter-study heterogeneity among their results \[[@b9-crt-2018-312]-[@b11-crt-2018-312]\]. Furthermore, there has been no spectrum study of *BRCA1/2* mutations in KoOC patients, such as nation-wide the Korean Hereditary Breast Cancer (KOHBRA) study \[[@b12-crt-2018-312],[@b13-crt-2018-312]\]; KOHBRA study included a total of 2,953 breast cancer patients with high risk of hereditary breast and ovarian cancer (HBOC) enrolled from 36 institutions between 2007 and 2013, covering approximately 2.9% of the total Korean breast cancer (KoBC) patients during the study period. Thus, we performed comprehensive analyses to estimate the prevalence, clinicopathological significance, spectrum, and penetrance of *BRCA1/2* mutations in a large cohort of KoOC patients.

Materials and Methods
=====================

1. Patients
-----------

A total of 279 EOC patients unselected for family history (FH) were enrolled between May 2012 and December 2017 from three investigational sites in Korea: the Pusan National University Hospital, Inje University Paik Hospital, and Kosin University Gospel Hospital (PIKO). Genetic testing of *BRCA1/2* genes in all three investigational hospitals was carried out by the Green Cross Company (Yongin, Korea) during the study period. The inclusion criteria for enrollment were primary EOC patients who had undergone staging surgery and had pathologically confirmed with EOC. Clinical and pathological data were collected for all patients: age at diagnosis, EOC grade, lymph node (LN) metastasis, FIGO stage (International Federation of Gynecology and Obstetrics, 2013), and personal history and FH of cancer. Patients with FH were defined as those with primary breast cancer or with first- or second-degree relatives with breast or ovarian cancer. FH of other cancer include all type of hematologic and non-hematologic malignancies.

2. Direct sequencing
--------------------

Genomic DNA was obtained from peripheral blood leukocytes and was extracted using the Promega DNA purification kit (catalog No. LA1620, Madison, WI) according to the manufacturer's instructions. All exon and intron boundaries of *BRCA1/2* were analyzed for mutations using a combination of denaturing high-performance liquid chromatography (WAVE DNA Fragment Analysis System, Transgenomic Inc., San Jose, CA) and bi-directional sequencing with a Big Dye Terminator V3.1 Cycle Sequencing Kit (Life Technologies, Carlsbad, CA) and ABI 3500xl (Life Technologies).

3. Statistical analyses
-----------------------

The Human Genome Variation Society nomenclature system (<http://www.hgvs.org/mutnomen>) was used for describing sequence variations, and the Breast Cancer Information Core (BIC) database (<http://research.nhgri.nih.gov/projects/bic/Member/index.shtml>) was used for evaluating results. Relationships among categorical variables were evaluated using t or chi-square tests. For all analyses, a p-value \< 0.05 was considered statistically significant. Analyses were performed using SPSS ver. 20.0 (IBM Corp., Armonk, NY).

4. Ethical statement
--------------------

This study was approved by the institutional review boards of the abovementioned three institutions. Informed consent was obtained from all participants, and peripheral blood samples were collected from each subject.

Results
=======

1. Prevalence of *BRCA1/2* mutations
------------------------------------

In our direct sequencing analysis of *BRCA1/2* genes in the 279 unselected EOC patients, pathogenic *BRCA1* and *BRCA2* mutations were observed in 35 (12.6%) and 11 (3.9%) cases, respectively. The overall prevalence of *BRCA1/2* mutations in KoOC patients was 16.5% ([Fig. 1A](#f1-crt-2018-312){ref-type="fig"}). Among the 279 EOC patients, 60 patients (21.5%) had FH of breast or ovarian cancer and 219 (78.5%) did not. The prevalence of *BRCA1/2* mutations was higher in the former (21 of 60, 35.0%) than in the latter (27 of 219, 12.3%) ([Fig. 1B](#f1-crt-2018-312){ref-type="fig"}). In specific subgroups according to tumor histology (serous vs. non-serous) and FIGO stage (I/II vs. III/IV), the prevalence of *BRCA1/2* mutations was 11.9 % in patients with early stage (I/II) and serous histology, 23.1% in patients with advanced stage (III/IV) and serous histology, 0% in patients with early stage (I/II) and non-serous histology and 16.7% in patients with advanced stage (III/IV) and non-serous histology ([S1 Fig.](#SD1-crt-2018-312){ref-type="supplementary-material"}).

2. Clinical characteristics of *BRCA1/2* mutations
--------------------------------------------------

Relationships between clinicopathological characteristics and *BRCA1/2* mutations are listed in [Table 1](#t1-crt-2018-312){ref-type="table"}. The mean ages at the time of onset for patients with and without *BRCA1/2* mutations were 53.7±9.6 years and 54.2±10.9 years, respectively, with no significant difference between them (p=0.765). In addition, we found no significant difference in the proportion of patients with early age-of-onset (\< 50 years) of ovarian cancers between *BRCA1/2*mutation carriers and non-carriers (39.1% vs. 30.5%, p=0.223). Patients with *BRCA1/2*mutations exhibited significantly higher rates of FH of breast or ovarian cancer (45.7%) and other cancers (39.1%) compared with those without *BRCA1/2* mutations (16.7% for FH of breast or ovarian cancer; 18.5% for FH of other cancers; both, p \< 0.001). The occurrence of serous histology was significantly higher in patients with *BRCA1/2* mutations (91.3%) than in those without *BRCA1/2* mutations (68.7%, p=0.002). Four patients with *BRCA1/2* mutations (8.7%) were identified as having non-serous histology in this study, with three cases of clear cell-type histology with *BRCA1* mutations and one case of endometrioid-type histology with a *BRCA2*mutation ([S2 Table](#SD2-crt-2018-312){ref-type="supplementary-material"}). In addition, patients with *BRCA1/2* mutations were more likely to be at an advanced FIGO stage of III/IV (87.0%) and exhibit LN metastasis (48.8%) than those without *BRCA1/2* mutations (61.4%, p=0.007 for advanced FIGO stage of III/IV; 28.8%, p=0.011 for LN metastasis) ([Table 1](#t1-crt-2018-312){ref-type="table"}). However, multivariate analysis using logistic regression identified FH of breast/ovarian cancer (p \< 0.001), serous histology (p=0.044), and advanced FIGO stage (III/IV, p=0.018) as the only factors showing independent correlation with *BRCA1/2* mutations (p \< 0.05) ([Table 2](#t2-crt-2018-312){ref-type="table"}).

3. Spectrum of *BRCA1/2*mutations
---------------------------------

All 46 pathogenic *BRCA1/2* mutations detected in this study are listed and summarized in [S2 Table](#SD2-crt-2018-312){ref-type="supplementary-material"}. Thirty-two distinct mutations were identified, including 21 in *BRCA1* and 11 in *BRCA2*. For a comprehensive analysis of the *BRCA1/2* mutation spectrum, all mutations reported in KoOC patients thus far were investigated and have been summarized in [Table 3](#t3-crt-2018-312){ref-type="table"}. To date, 111 mutations have been reported in KoOC patients, including 87 *BRCA1* mutations (78.4%) and 24 *BRCA2* mutations (21.6%) ([Fig. 2A](#f2-crt-2018-312){ref-type="fig"}). *BRCA1* mutations were more prevalent than *BRCA2* mutations, with a *BRCA1*-to-*BRCA2* prevalence ratio of 3.6:1. Of the 111 *BRCA1/2* mutations, 55 distinct mutations were identified, including 39 *BRCA1* and 16 *BRCA2* mutations. Among these pathologic 55 mutations, 24 (43.6%) were specific to Korean women and have not been previously reported in the BIC database ([Fig. 2C](#f2-crt-2018-312){ref-type="fig"}). Ten Korean population-specific mutations (18.2%) have not yet been reported in the KOHBRA study. Nineteen distinct mutations (19/55 distinct, 34.5%) were recurrent and were detected in at least two unrelated patients ([Fig. 2D](#f2-crt-2018-312){ref-type="fig"}). Of these recurrent mutations, five were highly recurrent and were found more than five times in unrelated patients: c.3627insA (n=14), c.390C\>A (n=8), c.922_923AGCinsT (n=5), c.5339T\>C (n=5), and c.3442delG (n=5) ([Table 4](#t4-crt-2018-312){ref-type="table"}). These five recurrent mutations account for 33.3% (37 of 111) of the mutations detected in the Korean population. These highly recurrent mutations were considered to be most likely the founder mutations in KoOC, and all of these have been reported in the KOHBRA study ([Table 4](#t4-crt-2018-312){ref-type="table"}).

Discussion
==========

In this study, we included 279 unselected EOC patients and comprehensively evaluated *BRCA1/2* mutations in the largest multicenter Korean cohort to date. We also analyzed the *BRCA1/2*mutation spectrum, including all mutation variants previously reported in KoOC. Across previous studies in Korea, the frequency of *BRCA1/2*mutations has reportedly been quite diverse, ranging between 23.8% and 31.9% \[[@b9-crt-2018-312]-[@b11-crt-2018-312]\] ([S3 Table](#SD3-crt-2018-312){ref-type="supplementary-material"}); this variation could have been caused by inter-study heterogeneity, including the differences in sample size, inclusion criteria, and the methods used for detecting mutation. In the present study, the overall frequency of *BRCA1/2* mutations in unselected KoOC patients was 16.5% ([Fig. 1A](#f1-crt-2018-312){ref-type="fig"}), which was comparable to the frequency of 13% to 15% in western cohorts \[[@b6-crt-2018-312],[@b14-crt-2018-312],[@b15-crt-2018-312]\]. In addition, the frequency of *BRCA1/2* mutations observed in the present study was comparable to the frequencies reported in other recent Asian reports, ranging from 11% to 17% \[[@b16-crt-2018-312]-[@b18-crt-2018-312]\]. These data suggest that there are no marked ethnic differences in the frequency of *BRCA1/2* mutations.

In terms of the age-of-onset, patients with *BRCA1/2* mutation are characterized by developing EOC at a younger age, based on a report of western cohorts \[[@b6-crt-2018-312]\]. Unlike the data for western cohorts, in this study, the mean age of patients with *BRCA1/2* mutation was not significantly lower than that of those without *BRCA1/2*mutation (53.7±9.6 years vs. 54.2±10.9 years, p=0.765). There were no significant differences in the proportion of patients with early age-of-onset (\< 50 years) of ovarian cancer between *BRCA1/2*mutation carriers and non-carriers (39.1% vs. 30.5%, p=0.223) in KoOC patients. Similarly to the present study, other studies including Asian populations have also shown no significant difference in the mean age-of-onset based on the presence or absence of *BRCA1/2*mutation \[[@b16-crt-2018-312]-[@b18-crt-2018-312]\]. Difference of genetic background and non-genetic factors, such as birth cohort and reproductive and lifestyle-related factors, could have influenced different results in Asian EOC patients.

Regarding the clinicopathological findings, patients with *BRCA1/2* mutations are characterized by serous histology \[[@b6-crt-2018-312],[@b19-crt-2018-312]\] and advanced stage with unfavorable outcomes \[[@b6-crt-2018-312],[@b19-crt-2018-312],[@b20-crt-2018-312]\]. In the present study, 91.3% (42/46 *BRCA1/2* mutation cases) had serous histology ([Table 1](#t1-crt-2018-312){ref-type="table"}). Only four cases (8.7%) with non-serous histology were identified, comprising three cases with clear carcinoma and one with endometrioid carcinoma. We did not find any other mucinous or mixed types ([S2 Table](#SD2-crt-2018-312){ref-type="supplementary-material"}). The fraction of serous carcinoma in KoOC patients with *BRCA1/2* mutation was comparable to those previously mentioned in some western reports. Our study also found that *BRCA1/2* mutations were significantly associated with an advanced FIGO stage of III/IV (p=0.007) and LN metastasis (p=0.011) ([Table 1](#t1-crt-2018-312){ref-type="table"}); in case of LN metastasis, it was not significant in multivariate logistic regression ([Table 2](#t2-crt-2018-312){ref-type="table"}).

Recently, two relatively large population-based studies including 95 and 916 women with unselected ovarian cancer were performed in Japan \[[@b17-crt-2018-312]\] and China \[[@b18-crt-2018-312]\], respectively, which are geographically close to Korea. On comparing three studies of East Asian populations, including the present Korean study, we found no marked ethnic differences in the *BRCA1/2* mutation frequency among the studies (12.6% in Japan, 16.7% in China, and 16.5% in Korea) ([Table 5](#t5-crt-2018-312){ref-type="table"}). These East Asian studies showed no significant difference in the mean age-of-onset between *BRCA1/2* mutation carriers and non-carriers (Japan, 57 years vs. 55 years; China, 53 years vs. 54 years; and Korea, 53 years vs. 54 years) ([Table 5](#t5-crt-2018-312){ref-type="table"}). In addition, these three studies revealed significant associations between *BRCA1/2* mutation and clinicopathological characteristics, including serous histology and advanced FIGO stage ([Table 5](#t5-crt-2018-312){ref-type="table"}). However, compared with EOC patients with *BRCA1/2* mutation in Korea and China, those in Japan showed a lower frequency of *BRCA1/2* mutation and higher mean age of onset. The high frequency of *BRCA2* mutations and the low proportion of FH of ovarian and/or breast cancer in Japanese EOC patients may have led to these differences in results, possibly indicating that the *BRCA1/2* mutation spectrum and/or founder mutations in Japanese EOC patients markedly differ from those in the other two countries.

Although only a few single-center studies including KoOC patients have been done, a large majority of spectrum analysis of *BRCA1/2*mutations in Korean HBOC patients was performed by the nationwide KOHBRA study \[[@b12-crt-2018-312],[@b13-crt-2018-312]\]. Among the 2,403 index patients, 378 were found to carry *BRCA1/2* mutations. Overall, 153 distinct mutations were identified, including 63 in *BRCA1* and 90 in *BRCA2*. When the *BRCA1/2* mutation spectrum was compared between KoOC and KoBC patients, the *BRCA1*-to-*BRCA2* ratio was 3.6:1.0 in KoOC and 1.0:1.4 in KoBC patients, representing that *BRCA1*mutations (78.4%) were predominant in KoOC ([Fig. 2A](#f2-crt-2018-312){ref-type="fig"}), whereas *BRCA2* mutations (59.2%) were predominant in KoBC ([Fig. 2B](#f2-crt-2018-312){ref-type="fig"}). In the KOHBRA study, a replacement mutation, c.7480C\>T, in the *BRCA2* gene, which was identified as a Korean founder mutation through haplotype analysis by Seong et al. \[[@b21-crt-2018-312]\], was the most commonly detected mutation, accounting for 10.1% of all *BRCA1/2* mutations ([Fig. 2B](#f2-crt-2018-312){ref-type="fig"}). In the present study of KoOC patients, c.3627insA in the *BRCA1* gene, was the most commonly detected mutation, accounting for 12.6% of all *BRCA1/2* mutations ([Fig. 2A](#f2-crt-2018-312){ref-type="fig"}), and c.7480C\>T was identified in only four unrelated EOC patients, accounting for 3.6% of all *BRCA1/2* mutations ([Table 3](#t3-crt-2018-312){ref-type="table"}). In our study, the *BRCA1/2*mutation spectrum varied according to the cancer type (ovarian and breast cancers) among the Korean HBOC population. The inconsistency of the *BRCA1/2* mutation spectrum between ovarian cancer and breast cancer in Korean HBOC was an unexpected result. Previously, Rebbeck et al. \[[@b22-crt-2018-312]\] investigated hazard ratios for breast and ovarian cancer based on mutation type, function, and nucleotide position in the international sample comprised of 19,581 *BRCA1/2*mutation carriers from 55 centers in 33 countries on six continents. They identified three breast cancer cluster regions (BCCRs) and one ovarian cancer cluster region (OCCR) in *BRCA1* and three BCCRs and three OCCRs in *BRCA2*, suggesting that breast and ovarian cancer risks were different by type and location of *BRCA1/2* mutations. These results support possible presence of mutation sequence-associated penetrance tendency according to cancer type, breast or ovarian cancer, in hereditary KoBOC. To elucidate the likelihood of mutation sequence-related penetrance tendency leading to breast or ovarian cancer in Korean HBOC, further studies regarding pooled database and risk assessment of *BRCA1/2* mutations for Korean HBOC are required.

The identification of recurrent mutations, including founder mutations, enables the development of cost-effective screening protocols and more efficient genetic counseling. In previous studies including Jewish populations \[[@b23-crt-2018-312]-[@b25-crt-2018-312]\], three mutations (*BRCA1* c.68_69delAG, c.5266dupC, and *BRCA2* c.5946delT) were identified as highly recurrent founder mutations, accounting for approximately 90% of all *BRCA1/2* mutations. In fact, screening based on these three founder mutations alone is currently ongoing in clinical practice for Ashkenazi Jewish individuals. In the present study, 65.4% (36 of 55 distinct) of *BRCA1/2* mutations were non-recurrent and the remaining 34.6% (19 of 55 distinct) were recurrent. Among the recurrent *BRCA1/2* mutations, five highly recurrent mutations, which were the candidates for Korean founder mutations, accounted for only 33.3% (37 of 111) of mutations detected in KoOC ([Table 4](#t4-crt-2018-312){ref-type="table"}). Considering the diversity of mutation spectrum and the low proportion of highly recurrent mutations in KoOC patients with *BRCA1/2* mutation, a screening protocol aimed at identifying highly recurrent founder mutations may not be effective. Currently, a full direct sequencing analysis for *BRCA1/2* is being performed in KoOC patients for the initial screening of HBOC.

Although this study is the first multi-center study in Korea, all the participating centers are located in the city of Busan, making our study less representative of the country as a whole. In addition, the absolute number of participants carrying *BRCA1/2*mutations was relatively small. Nevertheless, the prevalence and clinical significance, excluding the early onset of ovarian cancer, of *BRCA1/2* mutations in KoOC patients was not significantly different from the values reported in large population-based western studies. In this investigation, we found that KoOC and KoBC had different spectra of the *BRCA1/2* mutations; however, indirect analyses between KoOC and KoBC patients were conducted to compare the *BRCA1/2* mutation spectrum; herein, the data for KoBC patients were from the KOHBRA study. To confirm our results, further direct comparisons of *BRCA1/2*mutation spectra in a single cohort of Korean HBOC patients is required.

In conclusion, we demonstrated herein that KoOC patients with *BRCA1/2* mutation were significantly associated with several clinicopathologic factors, such as serous histology and an advanced FIGO stage. However, KoOC patients with *BRCA1/2* mutation were not characterized by an early age-of-onset (age \< 50) of ovarian cancer. An analysis of the *BRCA1/2* mutation spectrum in KoOC patients showed that the *BRCA1*-to-*BRCA2* ratio and the most commonly detected mutation were different from those of KoBC patients. Owing to the different mutation spectra of KoOC and KoOC patients among Korean HBOC, there were might be presence of possible penetrance tendency leading to breast cancer or ovarian cancer by mutation sequence-specific manner. Taken together, our observations may provide an insight for better genetic counseling and clinical surveillance for the at-risk relatives of KoOC patients.
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###### 

Association of *BRCA1/2* mutation status with clinicopathological characteristics in Korean ovarian cancer patients

  Characteristic                                             Total        *BRCA1/2* mutation--   *BRCA1/2* mutation+   p-value^[a)](#tfn1-crt-2018-312){ref-type="table-fn"}^
  ---------------------------------------------------------- ------------ ---------------------- --------------------- --------------------------------------------------------
  **Total**                                                  279 (100)    233 (83.5)             46 (16.5)             
  **Age (yr)**                                               54.15±10.7   54.2±10.9              53.7±9.6              0.765
  **Age, early-onset (age \< 50)**                                                                                     
   \< 50                                                     93 (33.3)    71 (30.5)              18 (39.1)             0.223
   ≥ 50                                                      186 (66.7)   162 (69.5)             28 (60.9)             
  **FHBOC^[b)](#tfn2-crt-2018-312){ref-type="table-fn"}^**                                                             
   No                                                        219 (78.5)   194 (83.3)             25 (54.3)             \< 0.001
   Yes                                                       60 (21.5)    39 (16.7)              21 (45.7)             
  **FH of other cancers**                                                                                              
   No                                                        218 (78.1)   190 (81.5)             28 (60.9)             \< 0.001
   Yes                                                       61 (21.9)    43 (18.5)              18 (39.1)             
  **Tumor histology**                                                                                                  
   Serous                                                    202 (72.4)   160 (68.7)             42 (91.3)             0.002
   Non-serous                                                77 (27.6)    73 (31.3)              4 (8.7)               
  **FIGO stage**                                                                                                       
   I/II                                                      96 (34.4)    90 (38.6)              6 (13.0)              0.007
   III/IV                                                    183 (65.6)   143 (61.4)             40 (87.0)             
  **LN metastasis**                                                                                                    
   No                                                        190 (68.1)   166 (71.2)             24 (51.2)             0.011
   Yes                                                       89 (31.9)    67 (28.8)              22 (48.8)             

Values are presented as number (%) or mean±standard deviation. FHBOC, family history of breast/ovarian cancer; FH, family history; FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node.

Continuous variables were analyzed using the Student's t test; categorical variables were analyzed using the chi-square test,

Patients with primary breast cancer or first- or second-degree relatives with breast or ovarian cancer.

###### 

Multivariate logistic regression in Korean ovarian cancer patients between *BRCA1/2* mutation status and clinicopathological characteristics

  Characteristic                                                      OR (95% CI)            p-value
  ------------------------------------------------------------------- ---------------------- ----------
  Age (\< 50 yr vs. ≥ 50 yr)                                          1.762 (0.861-3.605)    0.121
  FHBOC^[a)](#tfn3-crt-2018-312){ref-type="table-fn"}^ (yes vs. no)   9.089 (3.204-25.783)   \< 0.001
  FH of other cancers (yes vs. no)                                    1.223 (0.861-2.653)    0.747
  Tumor histology (serous vs. non-serous)                             3.834 (1.035-14.201)   0.044
  FIGO stage (III/IV vs. I/II)                                        3.738 (1.258-11.106)   0.018
  LN metastasis (yes vs. no)                                          1.143 (0.538-2.427)    0.729

OR, odds ratio; CI, confidence interval; FHBOC, family history of breast/ovarian cancer; FH, family history; FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node.

Patients with primary breast cancer or first- or second-degree relatives with breast or ovarian cancer.

###### 

Spectrum of *BRCA1/2* mutations in Korean ovarian cancer (KoOC) patients

  Site                         Mutation^[a)](#tfn4-crt-2018-312){ref-type="table-fn"}^     Type   No. of citations in KoOC^[b)](#tfn5-crt-2018-312){ref-type="table-fn"}^   No. of citations in BIC   No. of citations in KOHBRA
  ---------------------------- ----------------------------------------------------------- ------ ------------------------------------------------------------------------- ------------------------- ----------------------------
  ***BRCA1* (39 districts)**                                                                                                                                                                          
   2                           c.1A\>G                                                     MS     1 (1)                                                                     8                         NR
   6                           c.277_279delTTTinsCC                                        FS     1 (0)                                                                     0                         NR
   7                           c.390C\>A                                                   NS     8 (2)                                                                     1                         R
   11                          c.922_924AGCinsT                                            NS     5 (1)                                                                     0                         R
   11                          c.928C\>T                                                   NS     1 (0)                                                                     0                         R
   11                          c.981_982delAT                                              FS     1 (1)                                                                     13                        R
   11                          c.1179_1180dupAG                                            FS     2 (2)                                                                     0                         NR
   11                          c.1716delA                                                  FS     2 (1)                                                                     0                         R
   11                          c.1831delC                                                  NS     2 (2)                                                                     0                         R
   11                          c.1953delG                                                  FS     1 (1)                                                                     0                         NR
   11                          c.1962insT                                                  FS     2 (0)                                                                     0                         R
   11                          c.2047delA                                                  FS     1 (0)                                                                     0                         NR
   11                          c.2359delG                                                  FS     1 (0)                                                                     0                         R
   11                          c.2433delC                                                  FS     4 (1)                                                                     11                        R
   11                          c.2914G\>T                                                  NS     1 (0)                                                                     0                         R
   11                          c.3157delG                                                  FS     1 (0)                                                                     0                         R
   11                          c.3296delC                                                  FS     1 (0)                                                                     2                         R
   11                          c.3340G\>T                                                  NS     1 (0)                                                                     1                         R
   11                          c.3377_3378delATinsG                                        FS     1 (0)                                                                     0                         NR
   11                          c.3442delG                                                  FS     5 (2)                                                                     2                         R
   11                          c.3607C\>T                                                  NS     1 (0)                                                                     36                        R
   11                          c.3627insA                                                  FS     14 (5)                                                                    9                         R
   11                          c.3895C\>T                                                  NS     1 (0)                                                                     1                         R
   11                          c.3991C\>T                                                  NS     2 (1)                                                                     0                         R
   11                          c.4040_4041delGA                                            FS     1 (0)                                                                     0                         NR
   11                          c.4041_4042delAG                                            FS     2 (0)                                                                     0                         R
   16                          c.4801A\>T                                                  NS     1 (0)                                                                     2                         NR
   16                          c.4981G\>T                                                  NS     1 (1)                                                                     1                         R
   17                          c.5030_5033delCTAA                                          FS     1 (1)                                                                     17                        R
   18                          c.5080G\>T                                                  NS     1 (1)                                                                     12                        R
   18                          c.5102_5103delTG                                            FS     1 (0)                                                                     3                         R
   22                          c.5339T\>C^[c)](#tfn6-crt-2018-312){ref-type="table-fn"}^   MS     5 (2)                                                                     1                         NR
   23                          c.5444G\>A                                                  NS     2 (1)                                                                     4                         R
   23                          c.5445G\>A                                                  NS     3 (3)                                                                     0                         R
   24                          c.5470_5477delATTGGGCA                                      FS     1 (1)                                                                     2                         R
   24                          c.5496_5506delGGTGACCCGAGinsA                               FS     4 (4)                                                                     3                         R
   IVS5                        c.212+1G\>A                                                 SP     1 (0)                                                                     6                         R
   IVS6                        c.302-2A\>C                                                 SP     1 (1)                                                                     1                         R
   IVS23                       c.5467+1G\>A                                                SP     2 (0)                                                                     5                         R
  ***BRCA2* (16 districts)**                                                                                                                                                                          
   3                           c.276insA                                                   FS     1 (1)                                                                     1                         R
   10                          c.1111A\>T                                                  NS     1 (1)                                                                     0                         NR
   10                          c.1399A\>T                                                  NS     4 (1)                                                                     2                         R
   11                          c.2259delT                                                  FS     1 (1)                                                                     0                         R
   11                          c.2798_2799delCA                                            FS     1 (1)                                                                     1                         R
   11                          c.3599_3600delGT                                            FS     1 (0)                                                                     6                         R
   11                          c.3744_3747delTGAG                                          FS     1 (0)                                                                     8                         R
   11                          c.4207dupA                                                  FS     1 (1)                                                                     0                         NR
   11                          c.5576_5579delTTAA                                          FS     3 (1)                                                                     29                        R
   11                          c.5656C\>T                                                  NS     1 (1)                                                                     2                         R
   13                          c.6952C\>T                                                  NS     1 (1)                                                                     5                         R
   15                          c.7480C\>T                                                  NS     4 (0)                                                                     11                        R
   19                          c.8437_8439delGGA                                           IF     1 (0)                                                                     0                         NR
   20                          c.8572delC                                                  FS     1 (1)                                                                     0                         NR
   21                          c.8717_8718delAA                                            FS     1 (0)                                                                     0                         R
   25                          c.9431delC                                                  FS     1 (1)                                                                     0                         R

BIC, Breast Cancer Information Core; KOHBRA, Korean Hereditary Breast Cancer; NR, not reported; R, reported; MS, missense; NS, nonsense; FS, frameshift; SP, splicing.

Nomenclature system of the Human Genome Variation Society (<http://www.hgvs.org/mutnomen>),

Numbers in parentheses indicate repeated numbers in this study,

Recently implicated as a deleterious mutation rather than a variant of unknown significance.

###### 

Spectrum of highly frequent *BRCA1/2* mutations in Korean hereditary breast and ovarian cancer patients

  Gene      Site   Mutation^[a)](#tfn7-crt-2018-312){ref-type="table-fn"}^     Type   No. of citations in KoOC (%)   No. of citations in KOHBRA (%)
  --------- ------ ----------------------------------------------------------- ------ ------------------------------ --------------------------------
  *BRCA1*   11     c.3627insA                                                  FS     14 (12.6)                      9 (2.3)
  *BRCA1*   7      c.390C\>A                                                   NS     8 (7.2)                        21 (5.5)
  *BRCA1*   11     c.922_924AGCinsT                                            NS     5 (4.5)                        13 (3.4)
  *BRCA1*   22     c.5339T\>C^[b)](#tfn8-crt-2018-312){ref-type="table-fn"}^   MS     5 (4.5)                        0
  *BRCA1*   11     c.3442delG                                                  FS     5 (4.5)                        2 (0.5)

KoOC, Korean ovarian cancer; KOHBRA, Korean Hereditary Breast Cancer; FS, frameshift; NS, nonsense; MS, missense.

Nomenclature system of the Human Genome Variation Society (<http://www.hgvs.org/mutnomen>),

Recently implicated as a deleterious mutation rather than a variant of unknown significance.

###### 

Comparison of *BRCA1/2* mutations in unselected patients with ovarian cancer from three Asian countries

  Characteristic                                                                                    Japan Sakamoto et al. \[[@b17-crt-2018-312]\]   China Shi et al. \[[@b18-crt-2018-312]\]                       Korea This study
  ------------------------------------------------------------------------------------------------- ----------------------------------------------- -------------------------------------------------------------- ------------------
  **Total No.**                                                                                     95                                              916                                                            278
  **Overall prevalence of *BRCA1/2* mutations**                                                     12 (12.6)                                       153 (16.7)                                                     46 (16.5)
  **Prevalence of *BRCA1/2* mutations with FHBOC^[a)](#tfn9-crt-2018-312){ref-type="table-fn"}^**   6/36 (16.7)                                     39/84 (46.4)                                                   19/58 (32.8)
  **Ratio of *BRCA1:BRCA2* mutations (n:n)**                                                        1:1.4 (5:7)                                     3.3:1 (120:36)                                                 3.2:1 (35:11)
  **Age-of-onset, mean (yr)**                                                                                                                                                                                      
   *BRCA1/2* mutation+                                                                              57                                              53                                                             53
   *BRCA1/2* mutation--                                                                             55                                              54                                                             54
  **Serous histology**                                                                              12/12 (100)                                     131/153 (85.6)                                                 42/46 (91.3)
  **Advanced FIGO stage (III/IV)**                                                                  12/12 (100)                                     91/97^[b)](#tfn10-crt-2018-312){ref-type="table-fn"}^ (93.8)   40/46 (87.0)

Values are presented as number (%). FHBOC, family history of breast/ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics.

Patients with primary breast cancer or first- or second-degree relatives with breast or ovarian cancer,

Cases with unknown stage (n=56) were excluded.

[^1]: Byung Su Kwon and Jung Mi Byun contributed equally to this work.
